Targeted tumoricidal bacteria

Summary

Principal Investigator: R M Hoffman
Abstract: [unreadable] DESCRIPTION (provided by applicant): The goal of this application is to develop imageable tumor-targeting bacteria that can cure tumors without progressive infection of the host. Previous experiments by others employed anaerobic microorganisms for cancer therapy. Target specificity appeared largely due to the anaerobic requirements met principally in necrotic tumor areas. The resulting tumor killing was at best limited since anaerobic bacteria could not grow in viable tumor tissue. Therefore, more effective targeting is necessary, especially in the viable tumor tissue. Toward this goal, we have recently developed whole-body imaging systems that enable the visualization of green fluorescent protein (GFP)- and red fluorescent protein (RFP)- expressing tumors and bacteria (Nature Reviews Cancer 5, 796-806, 2005; Proc. Natl. Acad. Sci. USA 98, 9814-9818, 2001). With the help of the imaging technology, we have developed a unique tumor-targeting Salmonella typhimurium strain (Proc. Natl. Acad. Sci USA 102, 755-760, 2005). This strain is an auxotrophic but fully virulent variant of the facultative anaerobe Salmonella typhimurium, termed A1 that can grow under hypoxic or normoxic conditions. The A1 auxotrophic strain selectively grows in and destroys viable as well as necrotic malignant tissue but has little effect on normal tissue. The A1 bacteria eventually disappears from normal tissue even in immunodeficient nude mice. We rapidly selected this bacteria by labeling them with GFP and imaging their ability to target tumor labeled with RFP. This remarkable selectivity apparently reflects the imposed nutritional requirements that are apparently met only in the cancer cell milieu. S. typhimurium A1 is a double amino acid auxotroph that requires Leu and Arg. We have now demonstrated that human prostate and breast tumor mouse models have highly significant survival increases when treated with A1. The goal of this application is to expand the tumor types targeted by auxotrophic S. typhimurium and to determine if the host immune system enhances tumor kill by the bacteria. The specific aims are as follows: (1) Select additional multiple amino-acid auxotrophs of S. typhimurium to expand tumor-killing selectivity to additional tumor types, including patient tumor models; (2) Determine possible significance of host immunological status by comparing antitumor efficacy of selected S. typhimurium auxotrophs in nude-mouse and immunocompetent-mouse tumor models. In the Phase II grant, the effective antitumor bacterial strains will be further developed for eventual clinical application. Deletion mutants will be developed to reduce the probability of reversion of auxotrophs to wild-type. Determination of possible synergy of tumor targeting S. typhimurium auxotrophic strains and chemotherapeutic agents as well as radiology will also be tested in the Phase II application. Bacterial therapy for metastatic cancer is described. Genetically-altered bacteria that grow only in tumors and destroy them are being developed. Both bacteria and tumors are engineered to fluoresce different colors such that the targeting of the bacteria to the tumors can be visualized external to the mouse models being used. Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]
Funding Period: 2007-09-21 - 2008-08-31
more information: NIH RePORT

Top Publications

  1. pmc Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium
    Katsuhiro Hayashi
    AntiCancer, Inc, 7917 Ostrow Street, San Diego, CA 92111, USA
    J Cell Biochem 106:992-8. 2009
  2. ncbi Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium
    Katsuhiro Hayashi
    AntiCancer, Inc, San Diego, California, USA
    Cell Cycle 8:870-5. 2009
  3. ncbi Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice
    Chisa Nagakura
    AntiCancer, Inc, San Diego, CA 92111, U S A
    Anticancer Res 29:1873-8. 2009
  4. ncbi Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium
    H Kimura
    AntiCancer, Inc, San Diego, CA, USA
    Cell Prolif 43:41-8. 2010

Detail Information

Publications4

  1. pmc Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium
    Katsuhiro Hayashi
    AntiCancer, Inc, 7917 Ostrow Street, San Diego, CA 92111, USA
    J Cell Biochem 106:992-8. 2009
    ..No adverse effects were observed. This new strategy demonstrates the clinical potential of targeting and curing cancer metastasis with engineered bacteria without the need of toxic chemotherapy...
  2. ncbi Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium
    Katsuhiro Hayashi
    AntiCancer, Inc, San Diego, California, USA
    Cell Cycle 8:870-5. 2009
    ..RFP intensity of the lung metastasis was 3 +/- 1.5 x 10(6) in the untreated group and 0.42 +/- 0.33 x 10(6) in the treated group (p < 0.05). Therefore, bacterial treatment was effective for both primary bone tumor and lung metastasis...
  3. ncbi Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice
    Chisa Nagakura
    AntiCancer, Inc, San Diego, CA 92111, U S A
    Anticancer Res 29:1873-8. 2009
    ..After 7 days of treatment, the pancreatic cancer had regressed without the need of chemotherapy or any other treatment. This new strategy demonstrates the clinical potential of bacterial targeting for pancreatic cancer...
  4. ncbi Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium
    H Kimura
    AntiCancer, Inc, San Diego, CA, USA
    Cell Prolif 43:41-8. 2010
    ..In this study, we measured antitumour efficacy of the Salmonella typhimurium A1-R tumour-targeting bacterium strain, administered systemically or intrathecally, to spinal cord cancer in orthotopic mouse models...